Table 3

Serogroup A, C, Y, and W-135 rSBA GMTs and percentages of participants with a ≥4-fold rise in rSBA titer prior to and 28 days after vaccinationa

Vaccination groupResult for serogroup:
ACYW-135
GMT (95% CI), n% (95% CI) and no. with ≥4-fold increase in GMTGMT (95% CI), n% (95% CI) and no. with ≥4-fold increase in GMTGMT (95% CI), n% (95% CI) and no. with ≥4-fold increase in GMTGMT (95% CI)% (95% CI) and no. with ≥4-fold increase in GMT
PrevaccinationPostvaccinationPrevaccinationPostvaccinationPrevaccinationPostvaccinationPrevaccinationPostvaccination
PSV exposed
    MCV4651.5 (496.4–854.9), n = 1414,116 (3,469–4,885), 14065.7 (57.1–73.6), 13714.7 (9.9–22.0), 144288.3 (190.2–437), 14070.7 (62.4–78.1), 14078.8 (49.7–125.0), 1432,770 (2,197–3,493), 14079.9 (72.2–86.2), 13918.5 (11.8–29.0), 1432,436 (1,715–3,459), 14084.2 (77.0–89.8), 139
    MPSV4889.7 (669.5–1,132), 1383,833 (3,308–4,442), 13661.7 (52.8–69.9), 13315.8 (10.4–23.8), 141158.6 (99.7–252.0), 13657.4 (48.6–65.8), 13673.4 (44.7–120.7), 1411,936 (1,426–2,630), 13669.1 (60.6–76.8), 13624.5 (15.2–39.6), 1401,456 (958.1–2,212), 13472.2 (63.7–79.6), 133
PSV naïve
    MCV4441.1 (327.8–593.4), 1586,352 (5,508–7,324), 15885.8 (79.3–90.9), 15516.8 (11.1–25.4), 161993.4 (714.5–1,381.2), 16081.3 (74.3–87.0), 16016.8 (11.1–25.3), 1604,205 (3,458–5,112), 15995.6 (91.1–98.2), 1588.1 (5.6–11.8), 1606,927 (5,648–8,495), 15796.2 (91.8–98.6), 156
  • a rSBA, baby rabbit serum bactericidal antibody. PSV exposed means participants who received meningococcal polysaccharide vaccine before study entry. PSV naïve means participants who did not receive meningococcal polysaccharide vaccine before study entry. MCV4 indicates participants who received quadrivalent meningococcal conjugate vaccine. MPSV4 indicates participants who received quadrivalent meningococcal polysaccharide vaccine.